Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30104% above fair value
$170.26+2.68 (+1.60%)
Close on Nov 17, 2026Market cap $211.18BP/E –Yield 1.86%
Gilead Sciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Gilead Sciences's operating cash flow for the twelve months ending Sep 30, 2026 was $14.48B, up 49.8% year over year. For fiscal 2025 it was $10.02B, down 7.5% from the year before. Over ten years it grew -7.2% a year on average. The highest annual figure on record is $21.25B in fiscal 2015.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.02B | -7.5% |
| FY2024 | Dec 31, 2024 | $10.83B | +35.2% |
| FY2023 | Dec 31, 2023 | $8.01B | -11.8% |
| FY2022 | Dec 31, 2022 | $9.07B | -20.3% |
| FY2021 | Dec 31, 2021 | $11.38B | +39.4% |
| FY2020 | Dec 31, 2020 | $8.17B | -10.7% |
| FY2019 | Dec 31, 2019 | $9.14B | +8.9% |
| FY2018 | Dec 31, 2018 | $8.40B | -29.4% |
| FY2017 | Dec 31, 2017 | $11.90B | -30.2% |
| FY2016 | Dec 31, 2016 | $17.05B | -19.8% |
| FY2015 | Dec 31, 2015 | $21.25B | +65.8% |
| FY2014 | Dec 31, 2014 | $12.82B | +312.8% |
| FY2013 | Dec 31, 2013 | $3.11B | -2.8% |
| FY2012 | Dec 31, 2012 | $3.20B | -12.2% |
| FY2011 | Dec 31, 2011 | $3.64B | +28.4% |
| FY2010 | Dec 31, 2010 | $2.83B | -8.0% |
| FY2009 | Dec 31, 2009 | $3.08B | +43.7% |
| FY2008 | Dec 31, 2008 | $2.14B | +28.4% |
| FY2007 | Dec 31, 2007 | $1.67B | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $5.04B | +22.6% |
| Q2 FY2026 | Jun 30, 2026 | $3.57B | +332.0% |
| Q1 FY2026 | Mar 31, 2026 | $2.54B | +44.8% |
| Q4 FY2025 | Dec 31, 2025 | $3.33B | +11.8% |
| Q3 FY2025 | Sep 30, 2025 | $4.11B | -4.7% |
| Q2 FY2025 | Jun 30, 2025 | $827.00M | -37.6% |
| Q1 FY2025 | Mar 31, 2025 | $1.76B | -20.8% |
| Q4 FY2024 | Dec 31, 2024 | $2.98B | +37.2% |
| Q3 FY2024 | Sep 30, 2024 | $4.31B | +145.5% |
| Q2 FY2024 | Jun 30, 2024 | $1.33B | -43.3% |
| Q1 FY2024 | Mar 31, 2024 | $2.22B | +27.2% |
| Q4 FY2023 | Dec 31, 2023 | $2.17B | -15.5% |
| Q3 FY2023 | Sep 30, 2023 | $1.76B | -38.7% |
| Q2 FY2023 | Jun 30, 2023 | $2.34B | +29.7% |
| Q1 FY2023 | Mar 31, 2023 | $1.74B | -5.2% |
| Q4 FY2022 | Dec 31, 2022 | $2.57B | -19.9% |
| Q3 FY2022 | Sep 30, 2022 | $2.86B | -12.0% |
| Q2 FY2022 | Jun 30, 2022 | $1.80B | -22.2% |
| Q1 FY2022 | Mar 31, 2022 | $1.84B | -29.5% |
| Q4 FY2021 | Dec 31, 2021 | $3.21B | +67.3% |
| Q3 FY2021 | Sep 30, 2021 | $3.25B | +44.6% |
| Q2 FY2021 | Jun 30, 2021 | $2.32B | -9.7% |
| Q1 FY2021 | Mar 31, 2021 | $2.61B | +81.8% |
| Q4 FY2020 | Dec 31, 2020 | $1.92B | -25.7% |
| Q3 FY2020 | Sep 30, 2020 | $2.25B | -14.9% |
| Q2 FY2020 | Jun 30, 2020 | $2.57B | +9.6% |
| Q1 FY2020 | Mar 31, 2020 | $1.44B | -8.9% |
| Q4 FY2019 | Dec 31, 2019 | $2.58B | +10.0% |
| Q3 FY2019 | Sep 30, 2019 | $2.65B | +19.6% |
| Q2 FY2019 | Jun 30, 2019 | $2.34B | +48.9% |
| Q1 FY2019 | Mar 31, 2019 | $1.58B | -30.5% |
| Q4 FY2018 | Dec 31, 2018 | $2.35B | -14.8% |
| Q3 FY2018 | Sep 30, 2018 | $2.21B | -17.9% |
| Q2 FY2018 | Jun 30, 2018 | $1.57B | -55.4% |
| Q1 FY2018 | Mar 31, 2018 | $2.27B | -22.4% |
| Q4 FY2017 | Dec 31, 2017 | $2.75B | -22.2% |
| Q3 FY2017 | Sep 30, 2017 | $2.69B | – |
| Q2 FY2017 | Jun 30, 2017 | $3.53B | – |
| Q1 FY2017 | Mar 31, 2017 | $2.93B | – |
| Q4 FY2016 | Dec 31, 2016 | $3.54B | – |
See a number that looks wrong?